Changes to the Code
H.R. 7050 · Homeopathic Drug Product Safety, Quality, and Transparency Act · Introduced The text as a member of Congress first filed it. Most bills never get further than this.
In committee · step 2 of 5
21 U.S.C. § 321 Definitions; generally
3 changes the bill asks for here, 1 carried out
- Not carried out:
in paragraph (p), by striking
except a new animal drug or an animal feed bearing or containing a new animal drug
each place it appears and insertingexcept a new animal drug, an animal feed bearing or containing a new animal drug, or a homeopathic drug product
;The bill points to paragraph (p) of § 321, which isn't there in the Code as we have it. It may have been renumbered or removed since the bill was drafted.
Technical detail
target not found: no paragraph (p) in /us/usc/t21/s321 - Not carried out:
in paragraph (v), by inserting before the period at the end the following:
, and that a homeopathic drug product is not a new animal drug
; andThe bill points to paragraph (v) of § 321, which isn't there in the Code as we have it. It may have been renumbered or removed since the bill was drafted.
Technical detail
target not found: no paragraph (v) in /us/usc/t21/s321 - Carried out:
by adding at the end the following:
(tt) The term “homeopathic drug product” means a drug that— (1) contains 1 or more homeopathic ingredients; and (2) contains no other active ingredient. (uu) The term “homeopathic ingredient” means an ingredient— (1) listed in the Homeopathic Pharmacopoeia of the United States …
§ 321(ss)–(uu)
Start of § 321 to (ss) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (ss)(1) | (1) | (1) | ||
| an infant formula; or | an infant formula; or | |||
| (ss)(2) | (2) | (2) | ||
| a medical food, as defined in section 360ee(b)(3) of this title. | a medical food, as defined in section 360ee(b)(3) of this title. | |||
| (tt) | (tt) [inserted: ] | |||
| [inserted: The term “homeopathic drug product” means a drug that—] | ||||
| (tt)(1) | (1) [inserted: ] | |||
| [inserted: contains 1 or more homeopathic ingredients; and] | ||||
| (tt)(2) | (2) [inserted: ] | |||
| [inserted: contains no other active ingredient.] | ||||
| (uu) | (uu) [inserted: ] | |||
| [inserted: The term “homeopathic ingredient” means an ingredient—] | ||||
| (uu)(1) | (1) [inserted: ] | |||
| [inserted: listed in the Homeopathic Pharmacopoeia of the United States or a State homeopathic formulary; or] | ||||
| (uu)(2) | (2) [inserted: ] | |||
| [inserted: prepared pursuant to homeopathic safety and quality standards described in—] | ||||
| (uu)(2)(A) | (A) [inserted: ] | |||
| [inserted: the Homeopathic Pharmacopoeia of the United States or any other officially recognized homeopathic pharmacopoeia; or] | ||||
| (uu)(2)(B) | (B) [inserted: ] | |||
| [inserted: any accredited voluntary consensus standard for homeopathic drug products, as determined by the Secretary in compliance with section 12(d) of the National Technology Transfer and Advancement Act of 1995.] | ||||
21 U.S.C. § 360eee Definitions
1 change the bill asks for here, 1 carried out
- Carried out:
Section 581(13) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360eee(13)) is amended by striking
homeopathic drugs marketed in accordance with applicable guidance under this Act
and insertinghomeopathic drug products marketed in accordance with this Act
.
§ 360eee(12)–(15)
Start of § 360eee to (11)(B) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (12) | (12) Prescription drug | (12) Prescription drug | ||
| The term “prescription drug” means a drug for human use subject to section 353(b)(1) of this title. | The term “prescription drug” means a drug for human use subject to section 353(b)(1) of this title. | |||
| (13) | (13) Product | (13) Product | ||
| The term “product” means a prescription drug in a finished dosage form for administration to a patient without substantial further manufacturing (such as capsules, tablets, and lyophilized products before reconstitution), but for purposes of section 360eee–1 of this title, does not include blood or blood components intended for transfusion, radioactive drugs or radioactive biological products (as defined in section 600.3(ee) of title 21, Code of Federal Regulations) that are regulated by the Nuclear Regulatory Commission or by a State pursuant to an agreement with such Commission under section 2021 of title 42, imaging drugs, an intravenous product described in clause (xiv), (xv), or (xvi) of paragraph (24)(B), any medical gas (as defined in section 360ddd of this title), homeopathic | The term “product” means a prescription drug in a finished dosage form for administration to a patient without substantial further manufacturing (such as capsules, tablets, and lyophilized products before reconstitution), but for purposes of section 360eee–1 of this title, does not include blood or blood components intended for transfusion, radioactive drugs or radioactive biological products (as defined in section 600.3(ee) of title 21, Code of Federal Regulations) that are regulated by the Nuclear Regulatory Commission or by a State pursuant to an agreement with such Commission under section 2021 of title 42, imaging drugs, an intravenous product described in clause (xiv), (xv), or (xvi) of paragraph (24)(B), any medical gas (as defined in section 360ddd of this title), homeopathic [inserted: drug] [inserted: products ]marketed in accordance with this [inserted: Act], or a drug compounded in compliance with section 353a or 353b of this title. | |||
| (14) | (14) Product identifier | (14) Product identifier | ||
| The term “product identifier” means a standardized graphic that includes, in both human-readable form and on a machine-readable data carrier that conforms to the standards developed by a widely recognized international standards development organization, the standardized numerical identifier, lot number, and expiration date of the product. | The term “product identifier” means a standardized graphic that includes, in both human-readable form and on a machine-readable data carrier that conforms to the standards developed by a widely recognized international standards development organization, the standardized numerical identifier, lot number, and expiration date of the product. | |||
| (15) | (15) Quarantine | (15) Quarantine | ||
| The term “quarantine” means the storage or identification of a product, to prevent distribution or transfer of the product, in a physically separate area clearly identified for such use or through other procedures. | The term “quarantine” means the storage or identification of a product, to prevent distribution or transfer of the product, in a physically separate area clearly identified for such use or through other procedures. |
Rest of § 360eee unchanged
21 U.S.C. § 379aa Serious adverse event reporting for nonprescription drugs
1 change the bill asks for here, 1 carried out
- Carried out:
Section 760(a)(2) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379aa(a)(2)) is amended to read as follows:
(2) Nonprescription drug.— The term nonprescription drug— (A) means a drug that is— (i) not subject to section 503(b); and (ii) not subject to approval in an application submitted under section 505; and (B) includes a homeopathic drug product..
§ 379aa(a)Definitions(1)–(3)
Start of § 379aa to (a)(1)(B) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (1)(C) | (C) | (C) | ||
| an event occurring from withdrawal from the drug; and | an event occurring from withdrawal from the drug; and | |||
| (1)(D) | (D) | (D) | ||
| any failure of expected pharmacological action of the drug. | any failure of expected pharmacological action of the drug. | |||
| (2) | (2) Nonprescription drug | (2) Nonprescription drug[inserted: .—] | ||
| The term | The term nonprescription drug— | |||
| (2)(A) | (A) | (A) | ||
| [inserted: means a drug that is—] | ||||
| (2)(A)(i) | (i) [inserted: ] | |||
| [inserted: not subject to section 503(b); and] | ||||
| (2)(A)(ii) | (ii) [inserted: ] | |||
| [inserted: not subject to approval in an application submitted under section 505; and] | ||||
| (2)(A) | ||||
| (2)(B) | (B) | (B) | ||
| [inserted: includes] [inserted: a] [inserted: homeopathic] [inserted: drug] [inserted: product]. | ||||
| (3) | (3) Serious adverse event | (3) Serious adverse event | ||
| The term “serious adverse event” is an adverse event that— | The term “serious adverse event” is an adverse event that— | |||
| (3)(A) | (A) | (A) | ||
| results in— | results in— | |||
Rest of § 379aa unchanged
42 U.S.C. § 262 Regulation of biological products
1 change the bill asks for here, 1 carried out
- Carried out:
Section 351(i)(1) of the Public Health Service Act (42 U.S.C. 262(i)(1)) is amended by adding at the end the following:
Such term does not include a homeopathic drug product (as defined in section 201 of the Federal Food, Drug, and Cosmetic Act).
.
§ 262(i)“Biological product” defined(1)–(2)
Start of § 262 to (h) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (i) | (i) “Biological product” defined | (i) “Biological product” defined | ||
| In this section: | In this section: | |||
| (1) | (1) | (1) | ||
| The term “biological product” means a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein, or analogous product, or arsphenamine or derivative of arsphenamine (or any other trivalent organic arsenic compound), applicable to the prevention, treatment, or cure of a disease or condition of human beings. | The term “biological product” means a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or derivative, allergenic product, protein, or analogous product, or arsphenamine or derivative of arsphenamine (or any other trivalent organic arsenic compound), applicable to the prevention, treatment, or cure of a disease or condition of human beings.[inserted: Such term does not include a homeopathic drug product (as defined in section 201 of the Federal Food, Drug, and Cosmetic Act).] | |||
| (2) | (2) | (2) | ||
| The term “biosimilar” or “biosimilarity”, in reference to a biological product that is the subject of an application under subsection (k), means— | The term “biosimilar” or “biosimilarity”, in reference to a biological product that is the subject of an application under subsection (k), means— | |||
| (2)(A) | (A) | (A) | ||
| that the biological product is highly similar to the reference product notwithstanding minor differences in clinically inactive components; and | that the biological product is highly similar to the reference product notwithstanding minor differences in clinically inactive components; and |
Rest of § 262 unchanged